REIMAGINE trials demonstrate efficacy of combination therapy for treating type 2 diabetes

ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted

An interview with Dr. Rita Kalyani, the ADA's chief scientific and medical officer, discussing key research presented at the ADA 2026 Scient

Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial

A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial

ADA 2026 Scientific Sessions: New GLP-1 Drugs and Diabetes Research Highlights

In this JAMA Medical News podcast, Jennifer Abbasi interviews Dr. Rita Kalyani, the ADA's Chief Scientific and Medical Officer, about key hi

Study: GLP-1 drugs like semaglutide linked to lower amputation risk in diabetes patients with peripheral artery disease

A new study suggests that GLP-1 receptor agonists (like Ozempic and Wegovy) are associated with better outcomes in people with type 2 diabet

Semaglutide Shows Chondroprotective Effects in Osteoarthritis Through Weight Loss-Independent Metabolic Mechanism

This research article demonstrates that semaglutide, a GLP-1 receptor agonist, provides chondroprotective effects in osteoarthritis mouse mo

GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)